Future oncology最新文献_第6页

Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer. 精确肿瘤学液体活检的最新进展：新兴生物标志物及其在肺癌中的临床应用。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-05 DOI: 10.1080/14796694.2025.2542051

Tancredi Didier Bazan Russo, Francesco Pepe, Valerio Gristina, Andrea Gottardo, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Giulia Busuito, Lorena Incorvaia, Juliette Aimee Guerry, Antonio Galvano, Giuseppe Badalamenti, Viviana Bazan, Giancarlo Troncone, Antonio Russo, Umberto Malapelle

{"title":"Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer.","authors":"Tancredi Didier Bazan Russo, Francesco Pepe, Valerio Gristina, Andrea Gottardo, Gianluca Russo, Claudia Scimone, Lucia Palumbo, Giulia Busuito, Lorena Incorvaia, Juliette Aimee Guerry, Antonio Galvano, Giuseppe Badalamenti, Viviana Bazan, Giancarlo Troncone, Antonio Russo, Umberto Malapelle","doi":"10.1080/14796694.2025.2542051","DOIUrl":"10.1080/14796694.2025.2542051","url":null,"abstract":"Lung Cancer (LC) remains the leading cause of cancer-related mortality. While Tissue Biopsy (TB) remains the gold standard for molecular profiling, its invasiveness and inability to provide real-time monitoring have led to the adoption of Liquid Biopsy (LB) as a minimally invasive alternative. By analyzing different circulating analytes such as cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs), Extracellular Vesicles (EVs), and Tumor-Educated Platelets (TEPs), LB offers a dynamic approach to assessing tumor heterogeneity, Minimal Residual Disease (MRD), and treatment resistance. Recent clinical trials have underscored their role in guiding therapy decisions and monitoring treatment response. In early-stage disease, several Randomized Clinical Trials (RCTs) have shown that ctDNA clearance predicts survival benefits in patients receiving neoadjuvant or perioperative Immune Checkpoint Inhibitors (ICIs). Additionally, adjuvant RCTs have confirmed the ctDNA prognostic role in post-surgical relapse risk assessment. Despite its transformative potential, challenges such as assay standardization, sensitivity limitations in early-stage disease, and regulatory barriers remain. As ongoing research continues to validate its clinical utility, LB is poised to become an indispensable tool in the precision management of LC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2803-2821"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144784141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of exosomal miR17-92a cluster and target genes with breast cancer risk. 外泌体miR17-92a簇和靶基因与乳腺癌风险的关系

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-29 DOI: 10.1080/14796694.2025.2539627

Ambreen Parvaiz, Azhar Mehmood, Muhammad Saeed, Mahmood Akhtar Kayani, Ishrat Mahjabeen

{"title":"Association of exosomal miR17-92a cluster and target genes with breast cancer risk.","authors":"Ambreen Parvaiz, Azhar Mehmood, Muhammad Saeed, Mahmood Akhtar Kayani, Ishrat Mahjabeen","doi":"10.1080/14796694.2025.2539627","DOIUrl":"10.1080/14796694.2025.2539627","url":null,"abstract":"Background: The present study aimed to explore the roles of exosomal microRNAs (miR-17, miR-19b, and miR-92a) and two target genes (PTEN and TGFβR2) in breast cancer risk.Methods: Expression analysis was performed using real-time PCR in a study cohort of 500 patients and 500 age- and sex-matched healthy controls.Results: The selected miRNAs (miR-17, p < 0.01; miR-19b, p < 0.01; miR-92a, p < 0.01) and TGFβR2 (p < 0.01) revealed an upregulated expression pattern, whereas downregulation of PTEN (p < 0.05) was observed in cancer patients compared to controls. A significant upregulated expression of miR-17, miR-92a, and TGFβR2 was observed in advanced clinical stages, advanced T-stage, advanced N-stage, and advanced M-stage in breast cancer patients.Conclusions: These findings demonstrate the oncogenic potential of the selected miRNAs, contributing to breast carcinogenesis. Further analysis showed an association between the expression deregulation of the selected molecules and increased cell proliferation and metastasis. miR-17 and TGFβR2 showed good diagnostic potential with AUCs of 0.708 and 0.909, respectively.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2731-2746"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407647/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians. 亚太地区晚期肺癌治疗、医患联盟、癌症污名和社会心理支持的导航：来自患者、护理人员和医生的观点。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-06-08 DOI: 10.1080/14796694.2025.2499511

Chee Khoon Lee, Xue Yang, Yasushi Goto, Kang Yun Lee, Hyung Seok Yim, Mark Brooke, Hisakazu Aoshima, Emiko Ando, Yiting Liu, Jane Tsai, Grace Kah Mun Low, Naomi Kishiwada, Simone Marie Cheng, Divashini Rajendran, Regina Gowindah, Soe Pwint Phoo Mon, Min Hee Hong

{"title":"Navigating advanced lung cancer care, patient-physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians.","authors":"Chee Khoon Lee, Xue Yang, Yasushi Goto, Kang Yun Lee, Hyung Seok Yim, Mark Brooke, Hisakazu Aoshima, Emiko Ando, Yiting Liu, Jane Tsai, Grace Kah Mun Low, Naomi Kishiwada, Simone Marie Cheng, Divashini Rajendran, Regina Gowindah, Soe Pwint Phoo Mon, Min Hee Hong","doi":"10.1080/14796694.2025.2499511","DOIUrl":"10.1080/14796694.2025.2499511","url":null,"abstract":"Background: Factors influencing holistic lung cancer care among advanced/metastatic non-small cell lung cancer (NSCLC) patients in Asia-Pacific are understudied. We identified gaps in lung cancer care from patients, caregivers, and physicians in Australia, Japan, Mainland China, South Korea, and Taiwan.Methods: Qualitative interviews and quantitative surveys were conducted among NSCLC patients with limited targeted treatment options, caregivers, and physicians. Patient-caregiver paired interviews (n = 15) were analyzed narratively and thematically; survey findings (70 patients, 106 physicians) were summarized descriptively. Descriptive analyses were performed with no formal hypothesis testing.Findings: While patients (53-66%) felt able to care for their condition, 47% were unaware of genetic mutations and 46% perceived delays in diagnosis (41-44% were unaware of symptoms/severity). Most physicians (78-90%) prioritized treatment discussions, 51% decided for patients, and 69% encouraged patient-led decisions. Patients (61-77%) relied on physician decisions; 71-76% prioritizing reduced recurrence and minimal side effects over physician recommendations (53%). Although patients (66%) felt cared for by their doctors, 24-31% felt their mental/physical well-being was not proactively addressed.Conclusion: This study identified significant gaps in lung cancer care, including patients' suboptimal disease and treatment knowledge, limited patient-physician shared decision-making, cancer stigma, and inadequate psychosocial support; underscoring the need for tailored interventions in Asia-Pacific.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2851-2865"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COLUMBUS part 1-7-year results for encorafenib and binimetinib in BRAF V600-mutant melanoma. 哥伦布部分1-7年的结果：encorafenib和binimetinib治疗BRAF v600突变黑色素瘤。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-24 DOI: 10.1080/14796694.2025.2536459

Dirk Schadendorf

引用次数: 0

ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine. ABC-12：在durvalumab （MEDI4736）联合顺铂/吉西他滨的一线研究中探索晚期胆道癌患者的微生物组。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-29 DOI: 10.1080/14796694.2025.2539018

Eleni Vrana, Hayley Timmins, Ashley Osborne, Rebecca Cox, Harpreet Wasan, Yuk Ting Ma, Arvind Arora, Olusola Faluyi, Roopinder Gillmore, Pippa Corrie, Paul Miller, Seema Arif, Joanna Canham, Charlotte Martin, Muhammad Riaz, Tongtong Shi, Melissa Frizziero, Victoria Foy, Richard A Hubner, Helen Morement, John Bridgewater, Richard Adams, Juan W Valle, Mairéad G McNamara

{"title":"ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.","authors":"Eleni Vrana, Hayley Timmins, Ashley Osborne, Rebecca Cox, Harpreet Wasan, Yuk Ting Ma, Arvind Arora, Olusola Faluyi, Roopinder Gillmore, Pippa Corrie, Paul Miller, Seema Arif, Joanna Canham, Charlotte Martin, Muhammad Riaz, Tongtong Shi, Melissa Frizziero, Victoria Foy, Richard A Hubner, Helen Morement, John Bridgewater, Richard Adams, Juan W Valle, Mairéad G McNamara","doi":"10.1080/14796694.2025.2539018","DOIUrl":"10.1080/14796694.2025.2539018","url":null,"abstract":"Until recently, cisplatin/gemcitabine was standard of care for the first-line treatment of patients with advanced biliary tract cancer (BTC). The addition of durvalumab, an immune checkpoint inhibitor, to the combination of cisplatin/gemcitabine has demonstrated an overall survival (OS) benefit and is now a standard of care first-line treatment option. BTCs exhibit immunogenic features may develop through an accumulation of genetic and epigenetic alterations, and can be influenced by microbial exposure. Microbiota can influence inflammation and immunity, and its disruption may impair tumor response to immunotherapy and chemotherapy. Here, the rationale and design of the multi-center, single-arm ABC-12 trial (ISRCTN11210442) is described, which investigates the role of the microbiome in patients with advanced BTC in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine. The primary objective is to determine the difference in baseline alpha diversity between \"responders\" (partial or complete response) and \"non-responders\" at 18 weeks (RECIST 1.1) in patients treated with cisplatin/gemcitabine/durvalumab. Secondary objectives include investigating the association between microbiome parameters and objective response rate, tumor control (partial, complete response, and stable disease), progression-free and OS, and investigating the interaction between treatment effect and microbiome parameters on clinical outcomes.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2713-2721"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post-surgery recurrence predictors for stage I-II endometrial carcinoma: a retrospective observational study. I-II期子宫内膜癌术后复发预测因素：一项回顾性观察性研究。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-22 DOI: 10.1080/14796694.2025.2546281

Yushan Li, Hongli Wang, Shuyun Zhao

{"title":"Post-surgery recurrence predictors for stage I-II endometrial carcinoma: a retrospective observational study.","authors":"Yushan Li, Hongli Wang, Shuyun Zhao","doi":"10.1080/14796694.2025.2546281","DOIUrl":"10.1080/14796694.2025.2546281","url":null,"abstract":"Purpose: A retrospective observational study was conducted to investigate the predictors for recurrence of stage I-II endometrial cancer after surgical treatment.Methods: 130 stage I-II endometrioid carcinoma patients receiving laparoscopic surgery in Jincheng People's Hospital from January 2019 to January 2022 were retrospectively selected and diagnosed via HE assay. Their clinic and histology characteristics were collected. Kaplan-Meier survival analysis was to analyze the effect of chemotherapy and radiotherapy on the survival rate of the recurrent patients. Multivariate analysis was to explore the factors affecting postoperative recurrence.Results: Diagnosis was confirmed by diagnostic curettage in 129 cases. In 130 patients, the invading of superficial myometrium and deep myometrium was more obvious. After chemotherapy and radiotherapy treatment, the 5-year survival rate was 78.46%, and it was different among two therapies; (p = 0.006). Pathological type, disease stage, histological grade and myometrial invasion were the risk factors for recurrence. No significant difference in endometrioid adenocarcinoma proportion between 50 years old and ≤50 years old; (p > 0.05).Conclusion: The Stage I-II endometrial cancer recurrence after laparoscopic surgery can be judged by pathological type, disease stage, histological grade and myometrial invasion, providing theoretical basis for disease treatment to reduce the recurrence and improve the prognosis.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2867-2874"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma. t细胞参与治疗复发/难治性滤泡性淋巴瘤关键试验的临床代表性

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-13 DOI: 10.1080/14796694.2025.2543673

Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi

{"title":"Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma.","authors":"Zhijie Ding, Guihua Zhang, Junhua Yu, Tongsheng Wang, Rajesh Kamalakar, Savreet Bains Chawla, Anindit Chhibber, Anthony Wang, Abualbishr Alshreef, David Tybor, Felipe Marques Goncalves, Fernando Rivas Navarro, Mohammad Atiya, Elena Favaro, Alex Mutebi","doi":"10.1080/14796694.2025.2543673","DOIUrl":"10.1080/14796694.2025.2543673","url":null,"abstract":"Aim: To characterize trial populations of T-cell-engaging therapies, including bispecific antibodies and chimeric antigen receptor T-cell therapies, for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 systemic therapies and the extent to which they represent real-world R/R FL populations.Methods: Inclusion/exclusion criteria and baseline characteristics were compared descriptively for EPCORE NHL-1 (epcoritamab, N = 128), GO29781 (mosunetuzumab, N = 90), ELARA (tisagenlecleucel [tisa-cel], N = 97), and ZUMA-5 (axicabtagene ciloleucel [axi-cel], N = 124). Real-world data from the COTA Healthcare (New York, NY) and Optum Market Clarity (Eden Prairie, MN) databases contextualized the clinical representativeness of trial populations.Results: The epcoritamab trial enrolled a higher proportion of patients who were older, had higher Follicular Lymphoma International Prognostic Index scores, and were more double-refractory versus other trials. Notably, 37% of epcoritamab trial patients would have been excluded from the mosunetuzumab trial, 30% from the tisa-cel trial, and 29% from the axi-cel trial. These excluded subgroups were characterized by factors associated with poor clinical outcomes.Conclusion: The epcoritamab trial enrolled more broadly and was more representative of typical R/R FL patients than the mosunetuzumab, tisa-cel, and axi-cel trials. Differences in patient characteristics should be considered when evaluating the comparative benefits of T-cell engagers in R/R FL after ≥ 2 systemic therapies.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2795-2801"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144834905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. NEPA与阿瑞吡坦止吐方案预防化疗引起的恶心和呕吐的个体患者数据荟萃分析。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-08-09 DOI: 10.1080/14796694.2025.2542108

Rudolph M Navari, Timothy Tyler, Naoki Inui, Hirotoshi Iihara, Erminio Bonizzoni, Yeon Hee Park, Hope S Rugo, Eric J Roeland

{"title":"Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting.","authors":"Rudolph M Navari, Timothy Tyler, Naoki Inui, Hirotoshi Iihara, Erminio Bonizzoni, Yeon Hee Park, Hope S Rugo, Eric J Roeland","doi":"10.1080/14796694.2025.2542108","DOIUrl":"10.1080/14796694.2025.2542108","url":null,"abstract":"Aim: Because no conclusive data demonstrate superiority among NK1 receptor antagonists (RA), existing antiemetic guidelines regard them as interchangeable. This individual patient data (IPD) meta-analysis compared the efficacy of NEPA (netupitant/fosnetupitant) and aprepitant/fosaprepitant-based regimens in preventing chemotherapy-induced nausea and vomiting (CINV).Materials & methods: Head-to-head comparative studies published between 2003 and 2022 that evaluated antiemetic prophylaxis of aprepitant or fosaprepitant versus oral or intravenous (IV) NEPA in patients with various cancers receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) were identified through a literature search. We combined individual patient data to assess complete response (no emesis/no rescue medication) and no significant nausea using a two-stage approach.Results: A total of six studies involving 2,767 patients were included evaluating NEPA plus dexamethasone versus aprepitant/fosaprepitant plus any 5-HT3RA plus dexamethasone for patients with cancer receiving HEC/MEC. Complete response and no significant nausea rates were similar during the acute (0-24 h) phase but NEPA showed significantly higher rates than aprepitant during the delayed ( > 24-120 h) and overall (0-120 h) phases and on Days 3-5 following chemotherapy.Conclusion: Improved CINV prevention was observed with NEPA-based regimens, particularly during Days 3-5, highlighting its potential for managing prolonged nausea and vomiting associated with emerging anticancer targeted therapies.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2823-2833"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12407638/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144803959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma. 血清鞘氨醇-1-磷酸水平与egfr突变型肺腺癌脑转移相关

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2025-07-31 DOI: 10.1080/14796694.2025.2539059

Gang Xu, Yajie Li, Bo An, Bo Pan, Lihua Shang, Yan Yu, Dexin Jia

{"title":"Serum sphingosine-1-phosphate levels are associated with brain metastasis in EGFR-mutant lung adenocarcinoma.","authors":"Gang Xu, Yajie Li, Bo An, Bo Pan, Lihua Shang, Yan Yu, Dexin Jia","doi":"10.1080/14796694.2025.2539059","DOIUrl":"10.1080/14796694.2025.2539059","url":null,"abstract":"Aim: To investigate the association between serum sphingosine-1-phosphate (S1P) levels and brain metastasis in EGFR-mutant lung adenocarcinoma (LUAD).Methods: Serum S1P levels were analyzed in 103 LUAD patients. The baseline characteristics of the 103 patients in this study included the following: the overall cohort consisted of 50.49% males and 49.51% females. The average age of the cohort was 69.50 years (SD = 59.12). Regarding EGFR mutations, 52 patients (50.49%) had wild-type EGFR, 19 patients (18.45%) had EGFR Ex19Del, and 32 patients (31.07%) had the L858R mutation. Logistic regression models and competing risk Cox analyses were used to evaluate the association between S1P levels and brain metastasis. Kaplan-Meier curves assessed cumulative brain metastasis incidence over time.Results: Serum sphingosine-1-phosphate (SIP) levels were measured with the following results (mean ± SD): wild-type EGFR, 970.44 ± 344.37 nmol/L; Ex19Del, 1,246.41 ± 306.93 nmol/L; and L858R, 1,333.21 ± 385.08 nmol/L (p < 0.001). In EGFR-mutant patients, S1P levels were independently associated with increased risk of brain metastasis (OR = 8.2, p = 0.003; HR = 105, p < 0.001), whereas no significant association was observed in EGFR wild-type patients. Kaplan-Meier analysis revealed that high S1P levels were linked to earlier brain metastasis in EGFR-mutant patients (p = 0.0034). The relationship between S1P levels and brain metastasis was not significantly influenced by the presence of bone metastasis (p > 0.1).Conclusion: Elevated serum S1P levels are significantly associated with brain metastasis in EGFR-mutant LUAD patients. S1P may serve as a biomarker for brain metastasis risk and a potential therapeutic target.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2757-2765"},"PeriodicalIF":2.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144753196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An MRI-based radiomics nomogram to predict progression-free survival in patients with endometrial cancer. 预测子宫内膜癌患者无进展生存期的核磁共振成像放射组学提名图。

IF 2.6 4区医学

Future oncology Pub Date : 2025-09-01 Epub Date: 2024-09-17 DOI: 10.1080/14796694.2024.2398984

Ling Liu, Xiaodong Ji, Caihong Liang, Jinxia Zhu, Lixiang Huang, Yujiao Zhao, Xiangfeng Xu, Zhiyi Song, Wen Shen

引用次数: 0